HighGravityDataSigned in · PRO
Guidance history, every release
Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing
| Metric | Nov 7, 2024 FY24 Q4 | Feb 5, 2025 FY25 Q1 | May 1, 2025 FY25 Q2 | Aug 7, 2025 FY25 Q3 | Oct 9, 2025 FY25 Q4 | Feb 9, 2026 FY26 Q1 | Apr 2, 2026 FY26 Q2 | Aug 6, 2026 FY26 Q3 |
|---|---|---|---|---|---|---|---|---|
| For FY2026 | ||||||||
| Revenue growth (full year fiscal 2026) | — | — | — | — | — | — | — | New“toward the high end of its range” |
| Revenue Growth (FXN) | — | — | — | — | — | New“Low single-digit” | — | — |
| Adjusted Diluted EPS | — | — | — | — | — | New“$12.35 to $12.65” | — | Raised“$12.62 to $12.72” |
| Adjusted Diluted EPS Reported % Change | — | — | — | — | — | — | — | New“+6.1% to +6.9%” |
| Reported % Change (Adjusted Diluted EPS) | — | — | — | — | — | New“+4.7% to +7.2%” | — | — |
| Illustrative Foreign Currency (FX) Impact | — | — | — | — | — | New“~+120 basis points” | — | Lowered“~+100 basis points” |
| For FY2025 | ||||||||
| Adjusted Revenue Growth (FXN) | New“8.8% to 9.3%” | Reiterated“8.8% to 9.3%” | Lowered“7.8% to 8.3%” | Reiterated“7.8% to 8.3%” | — | — | — | — |
| GAAP Revenues | New“~$21.9 to $22.1 billion” | Lowered“~$21.7 to $21.9 billion” | Narrowed“~$21.8 to $21.9 billion” | Reiterated“~$21.8 to $21.9 billion” | — | — | — | — |
| Impact to organic revenue growth from expected decline in revenues in China and Bioscience and Pharma market dynamics | New“about 125 basis points” | — | — | — | — | — | — | — |
| Organic Revenue Growth | — | — | — | New“3.0% to 3.5%” | — | — | — | — |
| Organic Revenue Growth (FXN) | New“4.0% to 4.5%” | Reiterated“4.0% to 4.5%” | Lowered“3.0% to 3.5%” | — | — | — | — | — |
| Translational Foreign Currency Impact to Revenue | — | — | — | New“an increase of approximately $10 million to revenue year over year” | — | — | — | — |
| Adjusted Diluted EPS | New“$14.25 to $14.60” | Narrowed“$14.30 to $14.60” | Lowered“$14.06 to $14.34” | Raised“$14.30 to $14.45” | — | — | — | — |
| Adjusted Diluted EPS (before impact of tariffs) | — | — | New“$14.30 to $14.60” | — | — | — | — | — |
| Adjusted Diluted EPS Growth at Midpoint | — | — | — | New“9.4% growth at the midpoint” | — | — | — | — |
| Adjusted Diluted EPS growth at the midpoint | New“about 10%” | Reiterated“10%” | — | — | — | — | — | — |
| Adjusted Diluted EPS year-over-year growth | — | — | New“approximately 7.0% to 9.1%” | — | — | — | — | — |
| Fiscal 2025 adjusted diluted earnings per share (EPS) | — | — | — | — | New“at or above the midpoint of its previously issued guidance” | — | — | — |
| Translational Foreign Currency Impact to Adjusted EPS | — | — | — | New“about neutral to adjusted EPS” | — | — | — | — |
| Adjusted currency-neutral growth | New“8.8% to 9.3%” | — | — | — | — | — | — | — |
| Estimated tariff impact | — | — | New“approximately $0.25” | — | — | — | — | — |
| Headwind from translational foreign currency (full year) | — | — | New“approximately $0.05 or 40 basis points” | — | — | — | — | — |
| Share Buyback Commitment Completion | — | — | — | New“remaining $250 million of $1 billion share buyback commitment” | — | — | — | — |
| No period stated | ||||||||
| Intention to invest in U.S. manufacturing capacity | — | — | New“$2.5 billion” | — | — | — | — | — |
Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.